PT-141 drug, sold as Vyleesi, is an FDA-approved bremelanotide injection for low sexual desire. Learn dosing, side effects, timing, and safety.
PT-141 is the research name for bremelanotide, a prescription peptide the FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is given as a subcutaneous injection, not as a pill, and it acts on melanocortin receptors in the brain rather than on blood flow to the genitals. That makes it fundamentally different from erectile dysfunction drugs such as sildenafil or tadalafil.
What the PT-141 Drug Actually Is
PT-141 is a synthetic peptide that came out of sunless-tanning research. Scientists studying Melanotan II noticed that trial volunteers reported spontaneous erections, so they modified the molecule to isolate that effect. The result was bremelanotide, a smaller and more targeted peptide.
The essentials:
- Drug class: melanocortin receptor agonist, mainly MC4R
- Brand name: Vyleesi, bremelanotide injection, 1.75 mg
- Approved use: acquired, generalized HSDD in premenopausal women
- Route: subcutaneous injection in the abdomen or thigh
- Not approved: for men, for postmenopausal women, or as a nasal spray
Bremelanotide is not a cure for low libido, and it does not create desire out of nowhere. In the trials that supported approval, average improvements in desire and in related distress were modest, which is why it remains a niche option rather than a first-line treatment.
How PT-141 Works and How Fast It Kicks In
The peptide binds melanocortin receptors in the hypothalamus and limbic system — the same circuits involved in mood, appetite, and sexual motivation. Researchers believe it turns up the brain's desire signaling rather than improving genital blood flow, which is why it can affect interest and arousal even when vascular drugs have not helped.
The question pt-141 how long does it take to work has a fairly consistent answer. Label guidance directs users to inject at least 45 minutes before anticipated sexual activity, and most people notice an effect somewhere between 15 and 60 minutes afterward. Onset varies with injection site, body weight, and individual metabolism.
How long does pt-141 last? Most users report that effects fade within 2 to 6 hours, and the drug's half-life is roughly 2.7 hours. PT-141 is not a daily medication: dosing is capped at one injection per 24 hours and no more than eight injections per month.
Approved Dosing and Who Should Not Use It
The approved regimen is simple but strict:
- Inject 1.75 mg under the skin of the abdomen or thigh.
- Time the dose at least 45 minutes before sexual activity.
- Never exceed one dose in 24 hours or eight doses in a month.
- Rotate injection sites and avoid skin that is irritated, tender, or scarred.
Bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease, and prescribers are expected to check blood pressure before treatment begins. The drug has not been studied in postmenopausal women or in men, so any use outside the approved population is off-label.
Side Effects and pt 141 drug interactions
Nausea is the most common complaint, affecting roughly 40% of participants in clinical trials, followed by flushing, headache, injection site reactions, and vomiting. These effects are usually mild and short-lived, but they are frequent enough that some users stop treatment.
Anyone reviewing pt 141 drug interactions should know one reassuring fact: bremelanotide is a peptide broken down by proteolytic enzymes, not by the liver's cytochrome P450 system. That means it has fewer classic interactions than most oral medications. The main caution centers on blood pressure, so tell your prescriber about antihypertensives, stimulants, decongestants, and any other medication that shifts blood pressure.
Rarely, bremelanotide has been linked to focal hyperpigmentation — dark patches on the skin, gums, or breasts — particularly with repeated dosing. Report any new darkening to your prescriber.
Nasal Spray vs Injection
Every FDA-approved dose of bremelanotide is an injection. Intranasal formulations were studied in men in the early 2000s and showed some promise for erectile dysfunction, but absorption was inconsistent and blood pressure rose, so development shifted to subcutaneous delivery.
Today's pt-141 nasal spray products are compounded preparations or research chemicals. They are not FDA-approved, not standardized for purity or concentration, and not supported by the safety data behind Vyleesi. DIY nasal bremelanotide has grown alongside the peptide trend, but mixing raw powder with saline at home offers no way to confirm sterility, dose accuracy, or even the identity of the peptide.
| Feature | Subcutaneous Injection (Vyleesi) | Compounded Nasal Spray |
|---|---|---|
| FDA status | Approved for premenopausal women with HSDD | Not approved for any use |
| Dose accuracy | Fixed 1.75 mg per autoinjector | Varies by product and technique |
| Typical onset | 15 to 60 minutes | Reported as similar, but highly variable |
| Duration | About 2 to 6 hours | Unpredictable |
| Safety data | Published trials and label warnings | Little or none |
| Blood pressure effect | Monitored, transient increase | Unknown |
A direct pt-141 nasal spray vs injection comparison usually comes down to consistency, oversight, and risk. The injection delivers a known dose with published safety data, while a nasal spray delivers an unknown fraction of the dose with no regulatory review.
Safety, Legality, and where to buy pt-141
Bremelanotide is prescription-only in the United States, and it is not sold legally as a supplement or an over-the-counter product. People who search where to buy pt-141 outside a pharmacy usually land on research-chemical vendors, whose products are labeled "not for human consumption" for a reason.
Unregulated vials can contain the wrong peptide, the wrong concentration, or bacterial contamination. There is also no medical oversight, which matters for a drug that raises blood pressure and is contraindicated in cardiovascular disease.
If you are considering PT-141, talk with a healthcare professional about diagnosis, cardiovascular risk, and whether your symptoms fit the approved indication. PT-141 may help some people, but it is not a universal solution for low desire, and it should be used only under medical supervision.
Frequently Asked Questions
Is PT-141 FDA-approved?
Yes, bremelanotide is FDA-approved under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not approved for men, for postmenopausal women, or as a nasal spray. Nasal and research-chemical versions sold online are unapproved and unregulated.
How long does PT-141 take to work and how long does it last?
The injection is given at least 45 minutes before anticipated sexual activity, and most users report an effect within 15 to 60 minutes. Effects typically fade within 2 to 6 hours, and the drug's half-life is about 2.7 hours. Dosing is limited to one injection per 24 hours and eight injections per month.
Can I buy PT-141 without a prescription?
No. Bremelanotide is a prescription-only medication in the United States, and legitimate supply runs through licensed pharmacies. Vials sold as research chemicals online are not intended for human use and may contain the wrong peptide, the wrong dose, or contaminated material.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.